Molecular Insight Pharmaceuticals

Molecular Insight Pharmaceuticals, Inc. is focused on the research, development and commercialization of innovative molecular imaging pharmaceuticals and targeted radiotherapeutics to diagnose, treat and manage disease. The company's two lead compounds, Zemiva™ and Azedra™, are in advancing clinical programs. Molecular Insight has completed a Phase 2b clinical trial for its lead cardiology product candidate, Zemiva™ (Iodofiltic acid I 123, also known as BMIPP) and intends to begin a pivotal registration trial for Zemiva™ in the second half of 2006. Zemiva™ is a molecular imaging pharmaceutical in later stage clinical development for its first targeted indication to rapidly diagnose cardiac ischemia, or insufficient blood flow to the heart, in chest pain patients in the hospital emergency department setting. Approximately five to eight million patients in the United States present to emergency departments each year complaining of chest pain. Molecular Insight Pharmceuticals' lead oncology product candidate is a radiotherapeutic for cancer, Azedra™ (Ultratrace™ MIBG), an FDA-designated Orphan Drug with a Fast Track designation to treat metastatic neuroendocrine tumors. The company also has molecular imaging programs in cardiology, oncology and neurology. Molecular Insight's pipeline leverages proprietary technologies to target, visualize, treat and monitor disease.

Contact Details: 160 Second Street Cambridge Massachusetts 02142 United States of America Tel: 617.492.5554 Fax: 617.492.5664 Email: info@molecularinsight.com WWW: www.molecularinsight.com/

Loading...

Recent Publications by Molecular Insight Pharmaceuticals:
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Prostate-specific membrane antigen (PSMA) is expressed in normal human...	18th November, 2009	Molecular Insight Pharmaceuticals, Cambridge, Massachusetts, USA.	Cancer Res. 2009 Sep 1;69(17):6932-40. Epub 2009 Aug 25. DOI Direct Link
Comprehensive Radiolabeling, Stability, and Tissue Distribution Studies of Technetium-99m Single Amino Acid Chelates (SAAC). Technetium tricarbonyl chemistry has been a subject of interest in...	4th July, 2009	Molecular Insight Pharmaceuticals, Inc., 160 Second Street, Cambridge,	Bioconjug Chem. 2009 Jul 2. DOI Direct Link
A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. Prostate specific membrane antigen (PSMA) is a validated molecular marker...	24th February, 2009	Molecular Insight Pharmaceuticals, Inc., 160 Second Street, Cambridge,	J Med Chem. 2009 Jan 22;52(2):347-57. DOI Direct Link
Synthesis and evaluation of a series of 99mTc(CO)3+ lisinopril complexes for in vivo imaging of angiotensin-converting enzyme expression. In animal models of cardiac disease and in human congestive heart failure,...	29th July, 2008	Molecular Insight Pharmaceuticals Inc., Cambridge, Massachusetts 02142,	J Nucl Med. 2008 Jun;49(6):970-7. Epub 2008 May 15. DOI Direct Link

Press Releases on Molecular Insight Pharmaceuticals:
MichBio Announces Annual Business Meeting Keynote and Pre-Meeting Workshop	17th March, 2009	MichBio	ANN ARBOR, Mich., March 17 /PRNewswire-USNewswire/ -- MichBio, the association for Michigan biosciences, will host Harry Stylli, Ph.D., president and CEO of San Diego, CA-based Sequenom, Inc. as the

BioNews Results for Molecular Insight Pharmaceuticals:
Molecular Insight Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new	PR inside:  Nov 13 2009 3:07PM Matching: molecular insight pharmaceuticals
Molecular Insight Pharmaceuticals to Present at Lazard Capital Markets Annual Healthcare Conference	PR inside:  Nov 11 2009 8:22PM Matching: molecular insight pharmaceuticals
Molecular Insight Pharmaceuticals to Present at Lazard Capital Ma...	Zibb:  Nov 11 2009 9:42PM Matching: molecular insight pharmaceuticals
Molecular Insight Pharmaceuticals to Present at Lazard Capital Markets Annual Healthcare Conference	Earthtimes.org:  Nov 11 2009 8:22PM Matching: molecular insight pharmaceuticals
Molecular Insight Pharmaceuticals to Present at Lazard Capital Markets Annual Healthcare Conference	Market Wire:  Nov 11 2009 8:17PM Matching: molecular insight pharmaceuticals
Promote your company here: BioNewsCast - Press Release Distribution	→View more Molecular Insight Pharmaceuticals news.

Molecular Insight Pharmaceuticals Patents:
US Patent No.	Title
7556794	Pendant fatty acid imaging agents
7381399	Technetium-dipyridine complexes, and methods of use thereof
7317103	Imaging agents for diagnosis of Parkinson's disease
7314609	Stereoisomers of fatty acid analogs for diagnostic imaging
7179444	Pendant fatty acid imaging agents
→View more Molecular Insight Pharmaceuticals patents.

Molecular Insight Pharmaceuticals (MIPI) Financial information Links from Barchart
MIPI Quote from from Barchart.com
MIPI Chart from from Barchart.com
MIPI Profile from from Barchart.com
MIPI Opinion from from Barchart.com
→View more Molecular Insight Pharmaceuticals finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 334 times since April 2007, the link to the organisation's website has been followed 48 times

Search for more companies in Cambridge

Search for more companies in Massachusetts

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Molecular Insight Pharmaceuticals